/ VNDA
/ Market Analysis
Vanda (VNDA) Stock Skyrockets on FDA Approval for Bipolar, Schizophrenia Drug
Vanda stock jumped more than 40% in premarket trading after the FDA approved its new drug BYSANTI for Bipolar I disorder and schizophrenia.
February 23, 2026
Why Is VNDA Stock Surging Premarket? FDA Approves Motion Sickness Drug
Vanda Pharmaceuticals stock surged nearly 19% in premarket trading after receiving FDA approval for NEREUS, the first new motion sickness treatment in over 40 years, with the company expecting to ...
December 31, 2025
Back to 
